Top three Bayer shareholder Harris Associates on Thursday came out in strong support of the drugmaker’s CEO for suspending work on a separation of the diversified group and to focus on improving the company’s operating performance.
Tag Archive for: shareholders
Like the quest to discover a new medicine, pulling off a successful mega-deal is a frustrating and elusive experiment. Tokyo-based drugmaker Takeda understands the difficulty of both. Although boss Christophe Weber will have plenty to celebrate on the upcoming fifth anniversary of his landmark $62 billion Shire acquisition, the deal has delivered no value to his shareholders.
For this 37th annual special report, Med Ad News editors rank the world’s top 50 companies that generate revenue from prescription medicines and healthcare products.
The company announced Monday its shareholders elected Susan Langer, current president of Souffle Therapeutics, to its board of directors, replacing her reputed romantic partner Alex Denner.
In its most recent leadership shake-up, the company announced that three of its directors and its board chair will not stand for re-election at Wednesday’s annual stockholder meeting.
Germany’s three biggest asset management groups said they would not vote for the re-election of Bayer Chairman Norbert Winkeljohann on Friday because of his numerous board commitments.
Bayer investor Jeff Ubben has contacted fellow shareholders in the German group, investors and sources familiar with the matter told Reuters, in an apparent attempt to rally support for big changes at the drugs-to-pesticides company.
A top-10 shareholder in Bayer on Tuesday called on the group’s supervisory board to replace chief executive Werner Baumann quickly, adding to investor pressure to restore trust and revive the German drugmaker’s sagging share price.
Bayer CEO Werner Baumann may be on the way out. For the past several years, Baumann has been in the sights of angry shareholders but has evaded an ouster. That soon may be over.
AstraZeneca Plc on Monday won the dismissal of a U.S. shareholder lawsuit claiming that it concealed problems in developing its COVID-19 vaccine, making it unlikely the treatment would win regulatory approval in the United States.
